Dr. Chamie on durability of UGN-101 in low-grade UTUC
“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.
In this video, Karim Chamie, MD, discusses the background of the study, “Long-term recurrence free survival following UGN-101 treatment for low-grade upper tract urothelial carcinoma,” presented at the 2021 American Urological Association Annual Meeting, and how it builds on previous studies. Chamie is an associate professor of urology and director of the Urologic Oncology Fellowship at the University of California, Los Angeles.
Ra223 plus SABR does not delay progression of oligometastatic HSPC
October 3rd 2024"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.
